Cardiff Oncology, Inc. (CRDF) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CRDF Hot Sheet
Join SI Premium – FREE
Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q3 EPS of ($0.17), $0.04 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $120 thousand versus the consensus estimate of $125 thousand.
For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CAI International (CAI) Misses Q3 EPS by 11c ; Offers Guidance
- Chime Financial, Inc. (CHYM) Tops Q3 EPS by 13c ; Offers Guidance
- Dave Inc. (DAVE) Tops Q3 EPS by 31c; offers guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
